Compare American Airlines Group Inc (AAL) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Airlines Group Inc vs Enveric Biosciences Inc — how do they compare? American Airlines Group Inc trades at $16.55 (market cap $11.38B), while Enveric Biosciences Inc trades at $1.37 (market cap $5.84M). The key difference: American Airlines Group Inc is far larger — about 1948.6× Enveric Biosciences Inc's market cap, and American Airlines Group Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| AAL | ENVB | |
|---|---|---|
Market Cap | $11.38B | $5.84M |
Sector | Industrials | Health |
52-Week High | $18.15 | $17.40 |
52-Week Low | $10.18 | $1.28 |
Enterprise Value | $38.97B | $932.52K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Airlines (AAL) trades at $17.20, down 4.02% amid sector rotation. The stock shows a bullish technical signal with strong moving average alignment, though RSI levels are mixed. Fundamentally, revenue grew to $54.63B in 2025, but net income fell sharply to $111M, reflecting margin pressure. Recent news highlights airline sector volatility, with fuel cost declines offering relief but broader market sentiment weighing on travel stocks.
Outlook remains cautious; analyst consensus is split with a $19.96 price target suggesting modest upside. Key risks include volatile fuel prices, competitive pressures, and high debt levels. Earnings consistency is critical for sustained recovery, with Q2 2026 results pivotal for confirming operational improvements.
ENVB trades at $1.48, up 2.07% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, with negative ROE and ROA, yet consistently beat earnings expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
The outlook is mixed: strong analyst support (75% buy ratings) and positive clinical updates contrast with deep losses and bearish technicals. Key risks include clinical trial outcomes and cash burn, while institutional financing provides near-term stability. Upside depends on successful drug development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
